Trials / Completed
CompletedNCT00317954
Spironolactone in Diabetic Nephropathy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 48 (planned)
- Sponsor
- Steno Diabetes Center Copenhagen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and bloodpressure lowering effect) of spironolactone 25 mg o.d. in type 1 and type 2 diabetic patients with albuminuria despite recommended antihypertensive treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spironolactone |
Timeline
- Start date
- 2003-09-01
- Completion
- 2005-07-01
- First posted
- 2006-04-25
- Last updated
- 2006-04-25
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00317954. Inclusion in this directory is not an endorsement.